Corline Biomedical AB (OM: CLBIO)
Health Care · Pharmaceuticals · SE
Skr19.00
+4.68% today · +48.8% 1Y
Corline Biomedical AB (OM: CLBIO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $50.09M and employs 13 people.
Over the last twelve months the share price has gained 48.8%, trading between 11.25 and 27.20.
Tweenvest scores Corline Biomedical AB across four factors: quality 53/100, value 51/100, growth 0/100. Its strongest factor is quality.
CLBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $50.09M
- Revenue (TTM)
- $1.12M
- P/E
- —
- EPS
- -0.57
- Dividend yield
- —
- Beta (5Y)
- 0.30
- 52-week high
- Skr27.20
- 52-week low
- Skr11.25
- Avg volume (3M)
- —
- Shares outstanding
- 26.13M
- Employees
- 13
- Next earnings
- —
About Corline Biomedical AB
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
- ISIN
- SE0006887451
- Founded
- 1991
- Listed since
- Jun 3, 2015
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.70 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.02 | -0.74% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.20 | +0.36% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.